Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Conditions: Cervical Cancers; Vulvar Cancer; Vaginal Cancer; CIN1; CIN2; CIN 3; AIS; Invasive Carcinoma; Mild Dysplasia of Vulva; Moderate Dysplasia of Vulva; Vin III; VaIN1; VaIN2; VaIN3; Genital Wart Interventions: Biological: 9-valent HPV Recombinant Vaccine; Biological: Placebo Sponsors: Shanghai Bovax Biotechnology Co., Ltd.; Chongqing Bovax Biopharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | China Health | Vaccines